Radiotherapy for Non-Hodgkin’s lymphoma: still standard practice and not an outdated treatment option

[1]  R. Advani,et al.  Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Sonali M. Smith,et al.  Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Michael Hauptmann,et al.  Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Ng,et al.  Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Fleming,et al.  Non-invasive monitoring of patient-derived orthotopic xenograft: An optimal system for rapid in vivo testing. , 2016 .

[6]  L. Specht.  Does Radiation Have a Role in Advanced Stage Hodgkin’s or Non-Hodgkin Lymphoma? , 2016, Current Treatment Options in Oncology.

[7]  J. Raemaekers,et al.  Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. , 2015, The New England journal of medicine.

[8]  S. Beriwal,et al.  What is the optimal management of early‐stage low‐grade follicular lymphoma in the modern era? , 2015, Cancer.

[9]  S. Beriwal,et al.  Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Mamot,et al.  Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. O'neill,et al.  Stereotactic Radiosurgery in the Treatment of Recurrent CNS Lymphoma. , 2015, World neurosurgery.

[12]  K. Hoang-Xuan,et al.  Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. , 2015, The Lancet. Oncology.

[13]  P. Johnson,et al.  IV. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types , 2015, Hematological oncology.

[14]  J. Armitage,et al.  Primary mediastinal large B-cell lymphoma. , 2015, Cancer treatment reviews.

[15]  Christine F. Wogan,et al.  Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. , 2015, International journal of radiation oncology, biology, physics.

[16]  D. Correa,et al.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. , 2015, Blood.

[17]  K. Dunleavy,et al.  FDG PET-CT in follicular lymphoma: a case-based evidence review. , 2015, Blood.

[18]  Zuofeng Li,et al.  Proton therapy in the management of non-Hodgkin lymphoma , 2015, Leukemia & lymphoma.

[19]  A. Omuro,et al.  Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide , 2015, Leukemia & lymphoma.

[20]  Z. Bortlíček,et al.  Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? , 2015, Leukemia & lymphoma.

[21]  S. Flamm,et al.  Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma , 2014, Cancer.

[22]  K. Herfarth,et al.  [Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study]. , 2014, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[23]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  K. Herfarth,et al.  Strahlentherapie (4 Gy vs. 24 Gy) von Patienten mit indolentem Non-Hodgkin-Lymphom , 2014, Strahlentherapie und Onkologie.

[26]  M. Weller.  The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. , 2014, Neuro-oncology.

[27]  C. Begg,et al.  Breast cancer after chest radiation therapy for childhood cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Eich,et al.  Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.

[29]  W. Hiddemann,et al.  How we manage follicular lymphoma , 2014, Leukemia.

[30]  A. Ng,et al.  Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2014, International journal of radiation oncology, biology, physics.

[31]  He Wang,et al.  Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma , 2014, Radiation Oncology.

[32]  C. Rübe,et al.  Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Yahalom.  Radiotherapy of Follicular Lymphoma: Updated Role and New Rules , 2014, Current Treatment Options in Oncology.

[34]  P. Hoskin,et al.  4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[35]  U. Schneider,et al.  Radiation-induced second malignancies after involved-node radiotherapy with deep-inspiration breath-hold technique for early stage Hodgkin Lymphoma: a dosimetric study , 2014, Radiation oncology.

[36]  Z. Bortlíček,et al.  Radiotherapy With Rituximab Is Better than Radiotherapy alone In First Line Treatment Of Localized Follicular Lymphoma. Time To Change a Standard Strategy , 2013 .

[37]  C. Rübe,et al.  Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Colan,et al.  Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association , 2013, Circulation.

[39]  D. Correa,et al.  Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Donaldson,et al.  Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. , 2013, International journal of radiation oncology, biology, physics.

[41]  David Cunningham,et al.  Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.

[42]  Catherine Thieblemont,et al.  Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[43]  Elaine S. Jaffe,et al.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. , 2013, The New England journal of medicine.

[44]  R. Gascoyne,et al.  The Outcome of Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in the R-CHOP Treatment Era , 2012 .

[45]  H. Eich,et al.  Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)) , 2012 .

[46]  S. Tofani,et al.  Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations , 2012, Radiation oncology.

[47]  M Ladetto,et al.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Cerhan,et al.  Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  S. Montoto.  Management of localized-stage follicular lymphoma: changing the paradigm? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Sehn.  Chemotherapy Alone for Localized Diffuse Large B-Cell Lymphoma , 2012, Cancer journal.

[51]  M. MacManus,et al.  Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  D. Lefkopoulos,et al.  Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. , 2012, International journal of radiation oncology, biology, physics.

[53]  S. Ferrero,et al.  Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.

[54]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[55]  A. Ferreri.  How I treat primary CNS lymphoma. , 2011, Blood.

[56]  P. Hoskin,et al.  Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  M. Reni,et al.  Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. , 2011, The Oncologist.

[58]  K. Herfarth,et al.  Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial , 2011, BMC Cancer.

[59]  B. O'neill,et al.  Whole-brain radiotherapy in primary CNS lymphoma. , 2011, The Lancet. Oncology.

[60]  Adele Seniori Costantini,et al.  InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. , 2010, Blood.

[61]  E. Thiel,et al.  High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. , 2010, The Lancet. Oncology.

[62]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[63]  L. Sehn.  A decade of R-CHOP. , 2010, Blood.

[64]  A. Zelenetz,et al.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Bourhis,et al.  Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  F. Cavalli,et al.  High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial , 2009, The Lancet.

[67]  J. Cerhan,et al.  Follicular lymphoma in the United States: first report of the national LymphoCare study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Martelli,et al.  Primary mediastinal large B-cell lymphoma. , 2008, Critical reviews in oncology/hematology.

[69]  Jon D Wilson,et al.  Primary central nervous system lymphoma. , 2008, Archives of pathology & laboratory medicine.

[70]  R. Tsang,et al.  Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma. , 2008, International journal of radiation oncology, biology, physics.

[71]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[72]  T. Molina,et al.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Baars,et al.  Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. , 2006, International journal of radiation oncology, biology, physics.

[74]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[75]  D. Neuberg,et al.  Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. , 2006, International journal of radiation oncology, biology, physics.

[76]  S. Skvortsov,et al.  Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells. , 2005, Journal of radiation research.

[77]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[78]  J. Earle,et al.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[80]  A. Hart,et al.  High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  J. Miller,et al.  Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. , 2001, Blood.

[82]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[83]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[84]  M. Gospodarowicz,et al.  Radiation therapy of localized non-Hodgkin's lymphoma. , 1977, Cancer treatment reports.

[85]  A. Voutilainen,et al.  [Treatment of malignant lymphoma]. , 1970, Nordisk medicin.

[86]  Hodgkin Lymphoma.  NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines , 2014 .

[87]  M. Williams,et al.  Recommendations for the use of radiotherapy in nodal lymphoma. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[88]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[89]  M. Ghielmini,et al.  Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  James Olen Armitage,et al.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. , 1997, Blood.